2024 CUDA Yanqi Lake Conference | Professor Xiongjun Ye Shares Recent Breakthroughs in Renal Cell Carcinoma Treatment

2024 CUDA Yanqi Lake Conference | Professor Xiongjun Ye Shares Recent Breakthroughs in Renal Cell Carcinoma Treatment

The ASCO-GU, a premier academic conference in urologic oncology, at the beginning of the year sparked academic enthusiasm in 2024, receiving over 140 abstracts related to renal cell carcinoma (RCC). Professor Xiongjun Ye from the Chinese Academy of Medical Sciences Cancer Hospital presented a report on the significant progress in RCC treatment from the ASCO-GU at the 4th Yanqi Lake Conference of the Chinese Medical Association Urology Surgery Branch, summarizing the essence for all to appreciate.
2024CUDA Conference | Professor Benkang Shi: Focus on Unmet Needs of mHSPC Patients, Achieve Stratified Treatment for Key Populations

2024CUDA Conference | Professor Benkang Shi: Focus on Unmet Needs of mHSPC Patients, Achieve Stratified Treatment for Key Populations

The current treatment status of mHSPC patients in China and the need for further improvement have drawn attention. Recently, at the "4th Annual Conference of the Urology Physicians Branch of the Chinese Medical Association (2024)" held in Beijing, Professor Benkang Shi from Qilu Hospital of Shandong University shared insights on "Long-term Management of mHSPC Patients with Novel Hormonal Therapy Schemes." Following the conference, "Oncology Frontier - Urology News" invited Professor Benkang Shi to share insights on the diagnosis and treatment status of mHSPC, stratification of key populations, and personalized treatment
2024CUDA Conference | Professor Qiang Wei: Early Initiation of Novel Hormonal Therapy Brings More Benefits to Patients

2024CUDA Conference | Professor Qiang Wei: Early Initiation of Novel Hormonal Therapy Brings More Benefits to Patients

The "4th Annual Conference of the Urology Physicians Branch of the Chinese Medical Association (2024)" was successfully held in Beijing from April 13th to 14th. During the conference, Professor Qiang Wei from West China Hospital, Sichuan University, shared insights on "Standard Treatment of mHSPC in the Era of Novel Hormonal Therapy." Subsequently, "Oncology Frontier - Urology News" invited Professor Qiang Wei to discuss the significance of early initiation of novel hormonal therapy for mHSPC patients, the comparison between dual and triple therapy, and precise treatment selection strategies.
BISC 2024丨Professor Junyan Qu: Interpretation of Anthrax Diagnosis and Treatment Plan (2023 Edition)

BISC 2024丨Professor Junyan Qu: Interpretation of Anthrax Diagnosis and Treatment Plan (2023 Edition)

Anthrax is a zoonotic infectious disease caused by Bacillus anthracis infection, which still occurs sporadically in some areas of China. Anthrax can manifest in various clinical forms, with pulmonary anthrax having a mortality rate of over 80% and requiring management as a Class A infectious disease. In order to further standardize the clinical diagnosis and treatment of anthrax, the National Health Commission issued the "Anthrax Diagnosis and Treatment Plan (2023 Edition)." At the recent Fourth National Congress of the Chinese Society of Infectious Diseases (BISC 2024), Professor Junyan Qu, the secretary-general of the conference and from the Infectious Diseases Center of West China Hospital, Sichuan University, interpreted the diagnosis and treatment plan based on case studies. The summary is presented below.
Professor Ning Shen ‘s Team: Mechanisms of Resistance to Cefiderocol in Highly Virulent Klebsiella pneumoniae | ESCMID Global 2024

Professor Ning Shen ‘s Team: Mechanisms of Resistance to Cefiderocol in Highly Virulent Klebsiella pneumoniae | ESCMID Global 2024

With the escalating issue of antimicrobial resistance globally, newly emerged resistant strains pose a serious threat to public health. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study by Professor Ning Shen 's team from Peking University Third Hospital (Abstract No.: E0451) focused on the resistance issues of cefiderocol, a drug not yet marketed in China. The study discovered that cefiderocol can induce resistance in vitro and amplify the blaSHV-12 gene. Long-read sequencing technology demonstrated its potential in the rapid and accurate detection of resistance gene amplification, offering a new tool for future resistance research.
Professor Hongfei Duan：Advances in Diagnosis and Treatment of Mycobacterium avium Complex (MAC) Pulmonary Disease

Professor Hongfei Duan：Advances in Diagnosis and Treatment of Mycobacterium avium Complex (MAC) Pulmonary Disease

Non-tuberculous mycobacteria (NTM) refers to all mycobacteria other than Mycobacterium tuberculosis and Mycobacterium leprae. NTM most commonly affect the lungs, causing NTM pulmonary disease (NTM-PD), which can even lead to disseminated disease in immunocompromised individuals. In recent years, with changes in the environment, updates in detection technology, and increased awareness among physicians, the incidence of NTM-PD has been steadily increasing, with Mycobacterium avium complex (MAC) pulmonary disease being the most common worldwide. At the recent Fourth National Conference of the Chinese Medical Association on Bacterial and Fungal Infections (BISC 2024), Professor Hongfei Duan from the Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, delivered a fascinating presentation titled "Advances in Diagnosis and Treatment of Mycobacterium avium Complex Pulmonary Disease," elucidating and analyzing the current status, challenges, and progress in the diagnosis and treatment of MAC pulmonary disease.
Professor Qingyuan Zhang: Treatment Strategies for HR+/HER2- Advanced Breast Cancer Patients After Progression on CDK4/6i+ET

Professor Qingyuan Zhang: Treatment Strategies for HR+/HER2- Advanced Breast Cancer Patients After Progression on CDK4/6i+ET

While CDK4/6 inhibitors plus endocrine therapy (ET) have become the standard first-line treatment for HR+/HER2- advanced breast cancer patients, there is currently no standardized recommendation for treatment strategies after progression on CDK4/6 inhibitors plus ET. At the "2024 National Breast Cancer Conference," "Oncology Frontier" had the privilege of inviting Professor Qingyuan Zhang from Harbin Medical University Cancer Hospital to discuss the factors to consider and the available treatment strategies for patients who have progressed on CDK4/6 inhibitors plus ET.
Professor Shaohua Zhang: “CSCO BC Guidelines” Updated, Evidence-Based, Leading Chinese Clinical Practice

Professor Shaohua Zhang: “CSCO BC Guidelines” Updated, Evidence-Based, Leading Chinese Clinical Practice

The "Chinese Society of Clinical Oncology (CSCO) Breast Cancer Diagnosis and Treatment Guidelines (2024 Edition)" ("CSCO BC Guidelines") have been updated again, incorporating richer evidence-based medicine from early to late stages, introducing more new treatment strategies and options. It has influenced the field of breast cancer treatment in China significantly. "Oncology Frontier" interviewed Professor Shaohua Zhang from The Fifth Medical Center of the People's Liberation Army General Hospital to discuss the highlights and clinical significance of the updated "CSCO BC Guidelines".
2024 National Breast Cancer Congress | Professor Yingying Xu: Reflections on Translational Research Based on Neoadjuvant Platforms

2024 National Breast Cancer Congress | Professor Yingying Xu: Reflections on Translational Research Based on Neoadjuvant Platforms

Currently, neoadjuvant therapy has become an optimized treatment modality for locally advanced and some early-stage breast cancers. It can optimize local surgery by downsizing tumors and provide efficacy and prognostic information to guide adjuvant therapy, thus improving survival. Moreover, it serves as an excellent platform for personalized treatment efficacy prediction and new drug development. Translational research based on neoadjuvant platforms has significant value in selecting benefiting populations, predicting effective regimens, and achieving personalized and precise treatments. At the "2024 National Breast Cancer Congress," Professor Yingying Xu from The First Affiliated Hospital of China Medical University delivered a speech titled "Reflections on Translational Research Based on Neoadjuvant Platforms," which we will introduce in this article.
EBMTChina’s Voice| Professor Tong Wu: Innovative Explorations in the Application of Hematopoietic Stem Cell Transplantation Technology

EBMTChina’s Voice| Professor Tong Wu: Innovative Explorations in the Application of Hematopoietic Stem Cell Transplantation Technology

The 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was held in Glasgow, UK, from April 14th to 17th, 2024. The conference focused on the latest developments in stem cell transplantation and cell therapy, pushing forward better clinical outcomes for patients with hematologic diseases and blood cancers. At this meeting, Dr. Gao's team presented six research findings, covering innovative explorations and practices in hematopoietic stem cell transplantation, as well as the combined application of CAR-T and hematopoietic stem cell transplantation. They shared advanced concepts and research findings, contributing China's wisdom to the global stage and sharing innovative results with the world. This article includes a translation and compilation of two posters from Professor Tong Wu’s team for the enjoyment of our readers.